Trial Profile
To assess benefits of Advagraf and Prograf in patients with different CYP3A5 genotypes after kidney transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Renal transplant rejection
- Focus Adverse reactions; Pharmacokinetics
- 03 Apr 2017 New trial record
- 01 Apr 2017 Results published in the Biomedicine and Pharmacotherapy